Drugs for Schizophrenia 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 20)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Antidepressive Agents |
|
Phase 3 |
|
|
|
2 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
3 |
|
Quetiapine Fumarate |
|
Phase 3 |
|
111974-72-2 |
|
4 |
|
Antipsychotic Agents |
|
Phase 3 |
|
|
|
5 |
|
Oxytocin |
Approved, Vet_approved |
Phase 2 |
|
50-56-6 |
53477758 439302 |
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
(Arg8)-vasopressin
(Arg8)-vasotocin
1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
50-56-6
AC1L9735
alpha-Hypophamine
Argipressin
Argpressin acetate
BCBcMAP01_000094
Biotinyl-(arg8)-vasopressin
C00746
CHEBI:492195
CHEBI:7872
CHEMBL395429
CID439302
Cys-tyr-ile-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-ile-GLN-asn-cys-pro-leu-gly-NH2
Cys-tyr-ile-THR-asn-cys-gly-leu-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-lys-gly-NH2
D00089
Disulfide bridge cys1-cys6
Gly-leu-pro-c
HS-2021
L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
|
MolPort-003-938-941
NCGC00167132-01
nchembio.184-comp2
O3251_SIGMA
O4375_SIGMA
Ocytocin
Oxitocina
OXT
Oxytocic hormone
Oxytocin
OXYTOCIN
Oxytocin (JP15/USP/INN)
Oxytocin (TN)
Oxytocin 10 usp units in dextrose 5%
Oxytocin 20 usp units in dextrose 5%
Oxytocin 5 usp units in dextrose 5%
Oxytocin acetate
Oxytocin injection
Oxytocine
Oxytocinum
Pitocin
Pitocin (TN)
Syntocinon
Syntocinon (TN)
TI-001
|
|
6 |
|
Olanzapine |
Approved, Investigational |
Phase 2 |
|
132539-06-1 |
4585 |
Synonyms:
132539-06-1
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC1L1IHS
AC-665
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
Lanzac
Lilly brand of olanzapine
LS-152313
LY 170053
LY-170052
|
LY-170053
Midax
MLS000759457
MLS001165781
MLS001195646
MLS001424057
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
olanzapina
Olanzapina
olanzapine
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
olanzapinum
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa intramuscular
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa zydis
Zyprexa Zydis
|
|
7 |
|
Rimonabant |
Approved, Investigational |
Phase 2 |
|
158681-13-1, 168273-06-1 |
104850 |
Synonyms:
[3H]SR141716A
168273-06-1
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
A 281
AC-163720
AC1L2XM5
AC-731
Acomplia
Acomplia (TN)
C14319
CHEMBL111
CID104850
D05731
DB06155
I06-0381
L000572
LS-128155
MolPort-003-850-185
N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride
|
NCGC00164572-01
nchembio.129-comp21
nchembio.552-comp16
Rimonabant
Rimonabant (JAN/USAN/INN)
Rimonabant [USAN:INN]
Rimoslim
Riobant
Slimona
SR 141716
SR 141716a
SR141,716A
SR141716
SR-141716
SR141716a
SR141716A
SR-141716A
STK642500
UNII-RML78EN3XE
Zimulti
ZINC01540228
|
|
8 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
9 |
|
Antiemetics |
|
Phase 2 |
|
|
|
10 |
|
Serotonin Uptake Inhibitors |
|
Phase 2 |
|
|
|
11 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
12 |
|
Hormones |
|
Phase 2 |
|
|
|
13 |
|
Anti-Obesity Agents |
|
Phase 2 |
|
|
|
14 |
|
Hormone Antagonists |
|
Phase 2 |
|
|
|
15 |
|
Serine |
Investigational, Nutraceutical |
Phase 2 |
|
56-45-1 |
5951 |
Synonyms:
(-)-Serine
(2S)-2-amino-3-Hydroxypropanoate
(2S)-2-amino-3-Hydroxypropanoic acid
(S)-(-)-Serine
(S)-2-amino-3-Hydroxypropanoate
(S)-2-amino-3-Hydroxy-propanoate
(S)-2-amino-3-Hydroxypropanoic acid
(S)-2-amino-3-Hydroxy-propanoic acid
(S)-2-Amino-3-hydroxypropanoic acid
(S)-a-amino-b-Hydroxypropionate
(S)-a-amino-b-Hydroxypropionic acid
(S)-alpha-amino-beta-Hydroxypropionate
(S)-alpha-amino-beta-Hydroxypropionic acid
(S)-b-amino-3-Hydroxypropionate
(S)-b-amino-3-Hydroxypropionic acid
(S)-beta-amino-3-Hydroxypropionate
(S)-beta-amino-3-Hydroxypropionic acid
(S)-Serine
(S)-α-amino-β-hydroxypropionate
(S)-α-amino-β-hydroxypropionic acid
2-amino-3-Hydroxypropanoate
2-amino-3-Hydroxypropanoic acid
3-Hydroxy-L-alanine
|
alpha-Amino-beta-hydroxypropionic acid
beta-Hydroxyalanine
beta-Hydroxy-L-alanine
b-Hydroxyalanine
b-Hydroxy-L-alanine
L Serine
L-(-)-Serine
L-2-amino-3-Hydroxypropionate
L-2-amino-3-Hydroxypropionic acid
L-3-Hydroxy-2-aminopropionate
L-3-Hydroxy-2-aminopropionic acid
L-3-Hydroxy-alanine
L-Ser
L-Serin
L-Serine
S
Ser
Serina
Serine
SERINE
Serinum
β-hydroxyalanine
β-hydroxy-L-alanine
|
|
16 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 2 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
Antemovis
|
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
Serotonine
sérotonine
thrombocytin
Thrombocytin
thrombotonin
Thrombotonin
|
|
17 |
|
Dopamine |
Approved |
|
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
18 |
|
Dopamine Agents |
|
|
|
|
|
19 |
|
Dopamine Antagonists |
|
|
|
|
|
20 |
|
Paliperidone Palmitate |
|
|
|
|
|
Interventional clinical trials:
(show all 11)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbreviated) |
Completed |
NCT00206128 |
Phase 3 |
Seroquel SR |
2 |
A Randomized Trial Administering Oxytocin vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia and Schizo-affective Disorder |
Unknown status |
NCT01598623 |
Phase 2 |
Oxytocin |
3 |
D-serine Antipsychotic Monotherapy for Treatment Refractory Schizophrenia |
Completed |
NCT00816894 |
Phase 2 |
D-serine;Olanzapine |
4 |
The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia |
Terminated |
NCT00547118 |
Phase 2 |
Rimonabant;Placebo |
5 |
Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan |
Unknown status |
NCT01357005 |
|
|
6 |
Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan |
Unknown status |
NCT01249079 |
|
|
7 |
Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan |
Unknown status |
NCT01077687 |
|
|
8 |
INVega Is Studied In an Observational Design in the Netherlands |
Completed |
NCT00697658 |
|
Paliperidone ER |
9 |
The Effectiveness of The Meta-cognitive Training Among Chronic Schizophrenia Patients Treated Within Community Support Groups in Poland. |
Completed |
NCT02187692 |
|
|
10 |
Cognitive Remediation Program for Hospitalized in the Long Term Patients With Deficit Schizophrenia : Impact on the Capacities of Autonomy |
Not yet recruiting |
NCT03407950 |
|
|
11 |
A Study on Etiological Factors of Schizophrenia |
Terminated |
NCT00155636 |
|
|
|